Insilico Medicine company
Insilico Medicine is dedicated to develop high-performance AI platform for drug development to treat cancer and age-related diseases
Investors
Technology:
AI Platform
Industry:
Artificial Intelligence
Headquarters:
Asia-Pacific (APAC)
Founded Date:
Jan 2014
Employees Number:
11-50
Funding Status:
Early Stage Venture
Investors Number:
16
Total Funding:
51300000
Estimated Revenue:
Less than $1M
Last Funding Date:
2020-04-20
Last Funding Type:
Series B
Register and Claim Ownership